We’re disrupting the status quo with our bold vision for young patients – to not only survive their cancer but thrive in their lives after treatment. While many children survive acute lymphoblastic leukemia, the most common type of pediatric blood cancer, the treatments are harsh and outdated. The long-term effects of current therapies can create severe life-threatening complications. And…